Neurocrine reported FY2025 revenue of $2.86 billion and Q1 2026 revenue of $815 million, making the thesis about whether profitable neuroscience growth can broaden while pipeline and commercialization risk stay controlled.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
